Business Wire
03 Oct 2026, 14:50 UTC · 2h ago
Impact · against what's priced in
Agenus provides high-confidence long-term survival data (48% at three years) for its botensilimab and balstilimab combination in recurrent ovarian cancer. The large sample size of the Phase 1b cohort reduces the risk profile for future regulatory filings and commercialization.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Agenus reported a 48% estimated three-year survival rate for botensilimab (BOT) plus balstilimab (BAL) in recurrent ovarian cancer.
Newannounced today
So whatPositive long-term efficacy in this cohort supports an accelerated path toward a BLA filing and potential revenue generation by FY2027.
More positive than 99% of claims this week
Continue reading
5 related stories
The 48% three-year survival rate and the large sample size of 400+ patients provide strong evidence of long-term efficacy, increasing the probability of a successful BLA filing.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
The three-year follow-up results are derived from the ovarian cancer cohort of the Phase 1b C-800-01 trial involving 400+ patients.
Newannounced today
So whatA sample size of 400+ provides higher statistical confidence than typical Phase 1b studies, reducing the risk of failure in subsequent Phase 2/3 trials.
More positive than 78% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company announced follow-up results from a Phase 1b clinical trial for its immuno-oncology treatments.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
4h ago
—
AGEN hasn't traded since this ran. Last close $8.36 (Oct 2); the reaction starts at the next open.
AGEN chart →
